Dr. Jordan Gladman is a seasoned science administrator with a background in molecular biology and biomedical research. He currently leads strategic efforts at the National Institute of Neurological Disorders and Stroke (NINDS) Office of the Director (OD), working to optimize organizational, budget, policy, and communication efforts in support of the institute's scientific priorities. In his role at the NINDS OD, Jordan has played a key role in enhancing operations and strengthening partnerships between science and administration, with the goal of accelerating research.
Before joining the NINDS OD, Jordan worked in the NIH Office of the Director as the Special Assistant to the NIH Principal Deputy Director, Larry Tabak. While in the NIH OD, he served as the executive secretary for the ACD Working Group on Enhancing Rigor, Transparency, and Translatability in Animal Research, leading the development of a final report to the ACD on June 11, 2021. Additionally, he helped to coordinate the 2020 presidential transition materials process, the reviews of the IC diversity and health disparities plans, and he helped with the early development of the UNITE initiative.
Prior to his work at the NIH Office of the Director, Jordan served as a Health Program Specialist in the NINDS Neurodegeneration Cluster, where he focused on the institute's response to the National Plan to Address Alzheimer's Disease and provided key coordination and support for the NINDS/NIH Alzheimer's Disease-Related Dementias (ADRD) extramural research program.
Jordan received his B.S. in Molecular Biology from Ohio Northern University, where he worked as an undergraduate research intern in the microbiology laboratories of the Aerosol Science division of Battelle Memorial Institute. He later obtained his Ph.D. from the Integrated Biomedical Science Graduate Program at The Ohio State University, where he characterized the mouse Smn gene and developed a knock-in Smn C>T mouse model of spinal muscular atrophy (SMA). After graduation, he joined the laboratory of Dr. Mani Mahadevan at the University of Virginia as a postdoctoral research associate, where he studied the molecular mechanism underlying myotonic dystrophy type 1 (DM1).